Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

References

• BlachS, ZeuzemS, MannsM; Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176. doi:10.1016/S2468-1253(16)30181-928404132
   PubMed Web of Science ®Google Scholar
• FosterGR, IrvingWL, CheungMC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224–1231. doi:10.1016/j.jhep.2016.01.02926829205
   PubMed Web of Science ®Google Scholar
• LiG, De ClercqE. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antiviral Res. 2017;142:83–122. doi:10.1016/j.antiviral.2017.02.01428238877
   PubMed Web of Science ®Google Scholar
• De ClercqE. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Rev Med Virol. 2015;25(4):254–267. doi:10.1002/rmv.184226043288
   PubMed Web of Science ®Google Scholar
• De ClercqE, LiG. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747. doi:10.1128/CMR.00102-1527281742
   PubMed Web of Science ®Google Scholar
• De ClercqE. C-nucleosides to be revisited. J Med Chem. 2016;59(6):2301–2311. doi:10.1021/acs.jmedchem.5b0115726513594
   PubMed Web of Science ®Google Scholar
• De ClercqE. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014;89(4):441–452. doi:10.1016/j.bcp.2014.04.00524735613
   PubMed Web of Science ®Google Scholar
• ChungRT, GhanyMG, KimAY; AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492. doi:10.1093/cid/ciy58530215672
   PubMed Web of Science ®Google Scholar
• PawlotskyJ-M, NegroF, AghemoA; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. doi:10.1016/j.jhep.2018.03.02629650333
   PubMed Web of Science ®Google Scholar
• KandaT, LauGKK, WeiL, et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13(2):103–109. doi:10.1007/s12072-018-9915-530539517
   PubMed Web of Science ®Google Scholar
• HedskogC, ParhyB, ChangS, et al. Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification. Open Forum Infect Dis. 2019;6(3):ofz076. doi:10.1093/ofid/ofz07630949527
   PubMed Web of Science ®Google Scholar
• ChenY, YuC, YinX, GuoX, WuS, HouJ. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 2017;6(1):e95. doi:10.1038/emi.2017.7729089588
   PubMed Web of Science ®Google Scholar
• ZhangY, ChenLM, HeM. Hepatitis C virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14(1):41. doi:10.1186/s12985-017-0710-z28231805
   PubMed Web of Science ®Google Scholar
• Rivero-JuarezA, BrievaT, FriasM, RiveroA. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol. 2018;14(9):901–910. doi:10.1080/17425255.2018.150676530058394
   PubMed Web of Science ®Google Scholar
• CotterTG, JensenDM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019;13:2565–2577. doi:10.2147/DDDT.S172512
   PubMed Web of Science ®Google Scholar
• EllisS. Chinese approval for Ascletis’ HCV drug is first homegrown success. Nat Biotechnol. 2018;36(8):675–676. doi:10.1038/nbt0818-675a
   PubMed Web of Science ®Google Scholar
• MarkhamA, KeamSJ. Danoprevir: first global approval. Drugs. 2018;78(12):1271–1276. doi:10.1007/s40265-018-0960-030117020
   PubMed Web of Science ®Google Scholar
• KimJL, MorgensternKA, LinC, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87(2):343–355. doi:10.1016/S0092-8674(00)81351-38861917
   PubMed Web of Science ®Google Scholar
• LoveRA, PargeHE, WickershamJA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 1996;87(2):331–342. doi:10.1016/S0092-8674(00)81350-18861916
   PubMed Web of Science ®Google Scholar
• MakLY, SetoWK, LaiCL, YuenMF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol. 2018;14(5):483–491. doi:10.1080/17425255.2018.147223629718748
   PubMed Web of Science ®Google Scholar
• JiangY, AndrewsSW, CondroskiKR, et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem. 2014;57(5):1753–1769. doi:10.1021/jm400164c23672640
   PubMed Web of Science ®Google Scholar
• DumontS, ChengW, SerebrovV, et al. RNA translocation and unwinding mechanism of HCV NS3 helicase and its coordination by ATP. Nature. 2006;439(7072):105–108. doi:10.1038/nature0433116397502
   PubMed Web of Science ®Google Scholar
• Svahn GustafssonS, EhrenbergA, SchmuckB, AnwarMI, DanielsonUH. Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants. J Med Chem. 2014;57(5):1802–1811. doi:10.1021/jm401690f24512311
   PubMed Web of Science ®Google Scholar
• RajagopalanR, MisialekS, StevensSK, et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry. 2009;48(11):2559–2568. doi:10.1021/bi900038p19209850
   PubMed Web of Science ®Google Scholar
• GaneEJ, RouzierR, HassaneinT, et al. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatol Int. 2016;10(3):478–487. doi:10.1007/s12072-015-9699-926886127
   PubMed Web of Science ®Google Scholar
• WeiL, ShangJ, MaY, et al. Efficacy and safety of 12-week interferon-based danoprevir regimen in patients with genotype 1 chronic hepatitis C. J Clin Transl Hepatol. 2019;7(3):221–225. doi:10.14218/JCTH.2019.0001831608213
   PubMed Web of Science ®Google Scholar
• XuX, FengB, GuanY, et al. Efficacy and safety of all-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin in treatment-naive noncirrhotic HCV genotype 1 patients: results from a phase 2/3 clinical trial in China. J Clin Transl Hepatol. 2019;7(3):213–220. doi:10.14218/JCTH.2019.0003331608212
   PubMed Web of Science ®Google Scholar
• EversonG, CooperC, HezodeC, et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int. 2015;35(1):108–119. doi:10.1111/liv.1247124517252
   PubMed Web of Science ®Google Scholar
• ZhengS, HuaR, XieQ, et al. MAKALU: twelve-week of treatment with ritonavir-boosted danoprevir plus peginterferon and ribavirin produces 96% SVR12 in HCV genotype 1-infected non-cirrhotic chinese patients [abstract no. LB010]. Hepatol Int. 2017.
   Google Scholar
• KaoJH, YuML, ChenCY, et al. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: a phase 2 study. J Gastroenterol Hepatol. 2018;33(8):1507–1510. doi:10.1111/jgh.1409629346834
   PubMed Web of Science ®Google Scholar
• GaneEJ, PockrosPJ, ZeuzemS, et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int. 2015;35(1):79–89. doi:10.1111/liv.1258824814388
   PubMed Web of Science ®Google Scholar
• FeldJJ, JacobsonIM, JensenDM, et al. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015;62(2):294–302. doi:10.1016/j.jhep.2014.09.01325239078
   PubMed Web of Science ®Google Scholar
• GaneEJ, RouzierR, Wiercinska-DrapaloA, et al. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother. 2014;58(2):1136–1145. doi:10.1128/AAC.01515-1324295986
   PubMed Web of Science ®Google Scholar
• Di BisceglieAM, GhalibRH, HamzehFM, RustgiVK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14(10):721–729. doi:10.1111/j.1365-2893.2007.00862.x17875007
   PubMed Web of Science ®Google Scholar
• FriedMW, ShiffmanML, ReddyKR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. doi:10.1056/NEJMoa02004712324553
   PubMed Web of Science ®Google Scholar
• McHutchisonJG, LawitzEJ, ShiffmanML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–593. doi:10.1056/NEJMoa080801019625712
   PubMed Web of Science ®Google Scholar
• ShiffmanML, Di BisceglieAM, LindsayKL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126(4):1015–1023; discussion 947. doi:10.1053/j.gastro.2004.01.014
   Web of Science ®Google Scholar
• CuypersL, LiG, LibinP, PiampongsantS, VandammeA-M, TheysK. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance. Viruses. 2015;7(9):5018–5039. doi:10.3390/v709285726389941
   PubMed Web of Science ®Google Scholar
• SorboMC, CentoV, Di MaioVC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39. doi:10.1016/j.drup.2018.01.00429525636
   PubMed Web of Science ®Google Scholar
• RomanoKP, AliA, AydinC, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8(7):e1002832. doi:10.1371/journal.ppat.100283222910833
   PubMed Web of Science ®Google Scholar
• SoumanaDI, Kurt YilmazN, AliA, PrachanronarongKL, SchifferCA. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. J Am Chem Soc. 2016;138(36):11850–11859. doi:10.1021/jacs.6b0645427512818
   PubMed Web of Science ®Google Scholar
• RomanoKP, AliA, RoyerWE, SchifferCA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A. 2010;107(49):20986–20991. doi:10.1073/pnas.100637010721084633
   PubMed Web of Science ®Google Scholar
• PalanisamyN, DanielssonA, KokkulaC, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99(1):12–17. doi:10.1016/j.antiviral.2013.04.01823648709
   PubMed Web of Science ®Google Scholar
• ZhouK, LiangZ, WangC, et al. Natural polymorphisms conferring resistance to HCV protease and polymerase inhibitors in treatment-naive HIV/HCV co-infected patients in China. PLoS One. 2016;11(6):e0157438. doi:10.1371/journal.pone.015743827341031
   PubMed Web of Science ®Google Scholar
• LiuG, CaiQ, LiZ, et al. Effect of drug resistance mutations on antiviral agents in HCV patients. Antivir Ther. 2016;21(5):369–375. doi:10.3851/IMP285225222865
   PubMed Web of Science ®Google Scholar
• MatthewAN, LeidnerF, NewtonA, et al. Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease. Structure. 2018;26(10):1360–1372 e1365. doi:10.1016/j.str.2018.07.00430146168
   PubMed Web of Science ®Google Scholar
• DickinsonBC, PackerMS, BadranAH, LiuDR. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014;5(1):5352. doi:10.1038/ncomms635225355134
   PubMed Web of Science ®Google Scholar
• KoizumiY, OhashiH, NakajimaS, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci U S A. 2017;114(8):1922–1927. doi:10.1073/pnas.161019711428174263
   PubMed Web of Science ®Google Scholar
• AliA, AydinC, GildemeisterR, et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013;8(7):1469–1478. doi:10.1021/cb400100g23594083
   PubMed Web of Science ®Google Scholar
• LimSR, QinX, SusserS, et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother. 2012;56(1):271–279. doi:10.1128/AAC.05636-1122064535
   PubMed Web of Science ®Google Scholar
• LenzO, VerbinnenT, LinTI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878–1887. doi:10.1128/AAC.01452-0920176898
   PubMed Web of Science ®Google Scholar
• SeiwertSD, AndrewsSW, JiangY, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52(12):4432–4441. doi:10.1128/AAC.00699-0818824605
   PubMed Web of Science ®Google Scholar
• ImhofI, SimmondsP. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011;53(4):1090–1099. doi:10.1002/hep.2417221480315
   PubMed Web of Science ®Google Scholar
• BrennanBJ, PoirierA, MoreiraS, et al. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Clin Pharmacokinet. 2015;54(5):537–549. doi:10.1007/s40262-014-0222-625488594
   PubMed Web of Science ®Google Scholar
• GaneEJ, RouzierR, StedmanC, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011;55(5):972–979. doi:10.1016/j.jhep.2011.01.04621354234
   PubMed Web of Science ®Google Scholar
• ThomasDL, ThioCL, MartinMP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. doi:10.1038/nature0846319759533
   PubMed Web of Science ®Google Scholar
• RaoH, WeiL, Lopez-TalaveraJC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29(3):545–553. doi:10.1111/jgh.1239824090188
   PubMed Web of Science ®Google Scholar